Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 320

1.

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial.

Mullane KM, Morrison VA, Camacho LH, Arvin A, McNeil SA, Durrand J, Campbell B, Su SC, Chan ISF, Parrino J, Kaplan SS, Popmihajlov Z, Annunziato PW; V212 Protocol 011 Trial Team.

Lancet Infect Dis. 2019 Sep;19(9):1001-1012. doi: 10.1016/S1473-3099(19)30310-X. Epub 2019 Aug 6. Erratum in: Lancet Infect Dis. 2019 Aug 23;:.

PMID:
31399378
2.

Efficient methane production from petrochemical wastewater in a single membrane-less microbial electrolysis cell: the effect of the operational parameters in batch and continuous mode on bioenergy recovery.

Arvin A, Hosseini M, Amin MM, Najafpour Darzi G, Ghasemi Y.

J Environ Health Sci Eng. 2019 Feb 6;17(1):305-317. doi: 10.1007/s40201-019-00349-y. eCollection 2019 Jun.

3.

Current In Vivo Models of Varicella-Zoster Virus Neurotropism.

Mahalingam R, Gershon A, Gershon M, Cohen JI, Arvin A, Zerboni L, Zhu H, Gray W, Messaoudi I, Traina-Dorge V.

Viruses. 2019 May 31;11(6). pii: E502. doi: 10.3390/v11060502. Review.

4.

Impact and Fracture Strength of Simulated Immature Teeth Treated with Mineral Trioxide Aggregate Apical Plug and Fiber Post Versus Revascularization.

Jamshidi D, Homayouni H, Moradi Majd N, Shahabi S, Arvin A, Ranjbar Omidi B.

J Endod. 2018 Dec;44(12):1878-1882. doi: 10.1016/j.joen.2018.09.008. Epub 2018 Nov 1.

PMID:
30390973
5.

HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay.

Yang E, Gardner MR, Zhou AS, Farzan M, Arvin AM, Oliver SL.

PLoS One. 2018 Oct 25;13(10):e0206365. doi: 10.1371/journal.pone.0206365. eCollection 2018.

6.

The C-terminus of varicella-zoster virus glycoprotein M contains trafficking motifs that mediate skin virulence in the SCID-human model of VZV pathogenesis.

Zerboni L, Sung P, Sommer M, Arvin A.

Virology. 2018 Oct;523:110-120. doi: 10.1016/j.virol.2018.08.003. Epub 2018 Aug 14.

PMID:
30119012
7.

Distinctive Roles for Type I and Type II Interferons and Interferon Regulatory Factors in the Host Cell Defense against Varicella-Zoster Virus.

Sen N, Sung P, Panda A, Arvin AM.

J Virol. 2018 Oct 12;92(21). pii: e01151-18. doi: 10.1128/JVI.01151-18. Print 2018 Nov 1.

8.

Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.

Winston DJ, Mullane KM, Cornely OA, Boeckh MJ, Brown JW, Pergam SA, Trociukas I, Žák P, Craig MD, Papanicolaou GA, Velez JD, Panse J, Hurtado K, Fernsler DA, Stek JE, Pang L, Su SC, Zhao Y, Chan ISF, Kaplan SS, Parrino J, Lee I, Popmihajlov Z, Annunziato PW, Arvin A; V212 Protocol 001 Trial Team.

Lancet. 2018 May 26;391(10135):2116-2127. doi: 10.1016/S0140-6736(18)30631-7. Epub 2018 May 24.

PMID:
29856344
9.

Age-Associated Differences in Infection of Human Skin in the SCID Mouse Model of Varicella-Zoster Virus Pathogenesis.

Zerboni L, Sung P, Lee G, Arvin A.

J Virol. 2018 May 14;92(11). pii: e00002-18. doi: 10.1128/JVI.00002-18. Print 2018 Jun 1.

10.

Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells.

Cavrois M, Banerjee T, Mukherjee G, Raman N, Hussien R, Rodriguez BA, Vasquez J, Spitzer MH, Lazarus NH, Jones JJ, Ochsenbauer C, McCune JM, Butcher EC, Arvin AM, Sen N, Greene WC, Roan NR.

Cell Rep. 2017 Jul 25;20(4):984-998. doi: 10.1016/j.celrep.2017.06.087.

11.

Varicella-Zoster Virus Glycoproteins: Entry, Replication, and Pathogenesis.

Oliver SL, Yang E, Arvin AM.

Curr Clin Microbiol Rep. 2016 Dec;3(4):204-215. doi: 10.1007/s40588-016-0044-4. Epub 2016 Sep 9.

12.

Scrotal testis size in unilateral non-palpable cryptorchidism, what it can and cannot tell: Study of a Middle Eastern population.

Shadpour P, Kashi AH, Arvin A.

J Pediatr Urol. 2017 Jun;13(3):268.e1-268.e6. doi: 10.1016/j.jpurol.2016.12.013. Epub 2017 Jan 21.

PMID:
28254240
13.

Treatment of a Developmental Groove and Supernumerary Root Using Guided Tissue Regeneration Technique.

Alizadeh Tabari Z, Homayouni H, Pourseyediyan T, Arvin A, Eiland D, Moradi Majd N.

Case Rep Dent. 2016;2016:2738569. Epub 2016 Nov 14.

14.

The Glycoprotein B Cytoplasmic Domain Lysine Cluster Is Critical for Varicella-Zoster Virus Cell-Cell Fusion Regulation and Infection.

Yang E, Arvin AM, Oliver SL.

J Virol. 2016 Dec 16;91(1). pii: e01707-16. doi: 10.1128/JVI.01707-16. Print 2017 Jan 1.

15.

Dysregulated Glycoprotein B-Mediated Cell-Cell Fusion Disrupts Varicella-Zoster Virus and Host Gene Transcription during Infection.

Oliver SL, Yang E, Arvin AM.

J Virol. 2016 Dec 16;91(1). pii: e01613-16. doi: 10.1128/JVI.01613-16. Print 2017 Jan 1.

16.

Varicella-Zoster Virus Activates CREB, and Inhibition of the pCREB-p300/CBP Interaction Inhibits Viral Replication In Vitro and Skin Pathogenesis In Vivo.

François S, Sen N, Mitton B, Xiao X, Sakamoto KM, Arvin A.

J Virol. 2016 Sep 12;90(19):8686-97. doi: 10.1128/JVI.00920-16. Print 2016 Oct 1.

17.

Role for the αV Integrin Subunit in Varicella-Zoster Virus-Mediated Fusion and Infection.

Yang E, Arvin AM, Oliver SL.

J Virol. 2016 Jul 27;90(16):7567-78. doi: 10.1128/JVI.00792-16. Print 2016 Aug 15.

18.

Mutational analysis of varicella-zoster virus (VZV) immediate early protein (IE62) subdomains and their importance in viral replication.

Khalil MI, Che X, Sung P, Sommer MH, Hay J, Arvin AM.

Virology. 2016 May;492:82-91. doi: 10.1016/j.virol.2016.02.012. Epub 2016 Feb 23.

19.

Longitudinal Kinetics of Cytomegalovirus-Specific T-Cell Immunity and Viral Replication in Infants With Congenital Cytomegalovirus Infection.

Chen SF, Holmes TH, Slifer T, Ramachandran V, Mackey S, Hebson C, Arvin AM, Lewis DB, Dekker CL.

J Pediatric Infect Dis Soc. 2016 Mar;5(1):14-20. doi: 10.1093/jpids/piu089. Epub 2014 Sep 11.

20.

Dissecting the Molecular Mechanisms of the Tropism of Varicella-Zoster Virus for Human T Cells.

Sen N, Arvin AM.

J Virol. 2016 Jan 20;90(7):3284-7. doi: 10.1128/JVI.03375-14. Review.

21.

Single cell mass cytometry reveals remodeling of human T cell phenotypes by varicella zoster virus.

Sen N, Mukherjee G, Arvin AM.

Methods. 2015 Nov 15;90:85-94. doi: 10.1016/j.ymeth.2015.07.008. Epub 2015 Jul 23. Review.

22.

Differential effects of Sp cellular transcription factors on viral promoter activation by varicella-zoster virus (VZV) IE62 protein.

Khalil MI, Ruyechan WT, Hay J, Arvin A.

Virology. 2015 Nov;485:47-57. doi: 10.1016/j.virol.2015.06.031. Epub 2015 Jul 23.

23.

Neuronal Subtype and Satellite Cell Tropism Are Determinants of Varicella-Zoster Virus Virulence in Human Dorsal Root Ganglia Xenografts In Vivo.

Zerboni L, Arvin A.

PLoS Pathog. 2015 Jun 19;11(6):e1004989. doi: 10.1371/journal.ppat.1004989. eCollection 2015 Jun.

24.

A site of varicella-zoster virus vulnerability identified by structural studies of neutralizing antibodies bound to the glycoprotein complex gHgL.

Xing Y, Oliver SL, Nguyen T, Ciferri C, Nandi A, Hickman J, Giovani C, Yang E, Palladino G, Grose C, Uematsu Y, Lilja AE, Arvin AM, Carfí A.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):6056-61. doi: 10.1073/pnas.1501176112. Epub 2015 Apr 27.

25.

Varicella-zoster virus (VZV) origin of DNA replication oriS influences origin-dependent DNA replication and flanking gene transcription.

Khalil MI, Sommer MH, Hay J, Ruyechan WT, Arvin AM.

Virology. 2015 Jul;481:179-86. doi: 10.1016/j.virol.2015.02.049. Epub 2015 Mar 17.

26.

Autophagic flux without a block differentiates varicella-zoster virus infection from herpes simplex virus infection.

Buckingham EM, Carpenter JE, Jackson W, Zerboni L, Arvin AM, Grose C.

Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):256-61. doi: 10.1073/pnas.1417878112. Epub 2014 Dec 22.

27.

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.

Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, Gershon A, Gershon M, Levin MJ, Bezuidenhoudt M, Putzki N.

JAMA Neurol. 2015 Jan;72(1):31-9. doi: 10.1001/jamaneurol.2014.3065.

28.

Single-cell mass cytometry analysis of human tonsil T cell remodeling by varicella zoster virus.

Sen N, Mukherjee G, Sen A, Bendall SC, Sung P, Nolan GP, Arvin AM.

Cell Rep. 2014 Jul 24;8(2):633-45. doi: 10.1016/j.celrep.2014.06.024. Epub 2014 Jul 17.

29.

The cytoplasmic domain of varicella-zoster virus glycoprotein H regulates syncytia formation and skin pathogenesis.

Yang E, Arvin AM, Oliver SL.

PLoS Pathog. 2014 May 29;10(5):e1004173. doi: 10.1371/journal.ppat.1004173. eCollection 2014 May.

30.

Treatment of necrotic calcified tooth using intentional replantation procedure.

Moradi Majd N, Arvin A, Darvish A, Aflaki S, Homayouni H.

Case Rep Dent. 2014;2014:793892. doi: 10.1155/2014/793892. Epub 2014 Mar 4.

31.

Molecular mechanisms of varicella zoster virus pathogenesis.

Zerboni L, Sen N, Oliver SL, Arvin AM.

Nat Rev Microbiol. 2014 Mar;12(3):197-210. doi: 10.1038/nrmicro3215. Epub 2014 Feb 10. Review.

32.

Cellular transcription factor YY1 mediates the varicella-zoster virus (VZV) IE62 transcriptional activation.

Khalil MI, Sommer M, Arvin A, Hay J, Ruyechan WT.

Virology. 2014 Jan 20;449:244-53. doi: 10.1016/j.virol.2013.11.029. Epub 2013 Dec 12.

33.

Regulation of the varicella-zoster virus ORF3 promoter by cellular and viral factors.

Khalil MI, Sommer M, Arvin A, Hay J, Ruyechan WT.

Virology. 2013 Jun 5;440(2):171-81. doi: 10.1016/j.virol.2013.02.019. Epub 2013 Mar 21.

34.

ORF11 protein interacts with the ORF9 essential tegument protein in varicella-zoster virus infection.

Che X, Oliver SL, Reichelt M, Sommer MH, Haas J, Roviš TL, Arvin AM.

J Virol. 2013 May;87(9):5106-17. doi: 10.1128/JVI.00102-13. Epub 2013 Feb 20.

35.

Identification of a hydrophobic domain in varicella-zoster virus ORF61 necessary for ORF61 self-interaction, viral replication, and skin pathogenesis.

Wang L, Rajamani J, Sommer M, Zerboni L, Arvin AM.

J Virol. 2013 Apr;87(7):4075-9. doi: 10.1128/JVI.02963-12. Epub 2013 Jan 23.

36.

An immunoreceptor tyrosine-based inhibition motif in varicella-zoster virus glycoprotein B regulates cell fusion and skin pathogenesis.

Oliver SL, Brady JJ, Sommer MH, Reichelt M, Sung P, Blau HM, Arvin AM.

Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1911-6. doi: 10.1073/pnas.1216985110. Epub 2013 Jan 15.

37.

Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age.

Gans HA, Yasukawa LL, Sung P, Sullivan B, DeHovitz R, Audet S, Beeler J, Arvin AM.

J Infect Dis. 2013 Feb 15;207(4):574-82. doi: 10.1093/infdis/jis719. Epub 2013 Jan 8.

38.

Herpes simplex virus 1 tropism for human sensory ganglion neurons in the severe combined immunodeficiency mouse model of neuropathogenesis.

Zerboni L, Che X, Reichelt M, Qiao Y, Gu H, Arvin A.

J Virol. 2013 Mar;87(5):2791-802. doi: 10.1128/JVI.01375-12. Epub 2012 Dec 26.

39.
40.

The attenuated genotype of varicella-zoster virus includes an ORF0 transitional stop codon mutation.

Peters GA, Tyler SD, Carpenter JE, Jackson W, Mori Y, Arvin AM, Grose C.

J Virol. 2012 Oct;86(19):10695-703. doi: 10.1128/JVI.01067-12. Epub 2012 Jul 25.

41.

3D reconstruction of VZV infected cell nuclei and PML nuclear cages by serial section array scanning electron microscopy and electron tomography.

Reichelt M, Joubert L, Perrino J, Koh AL, Phanwar I, Arvin AM.

PLoS Pathog. 2012;8(6):e1002740. doi: 10.1371/journal.ppat.1002740. Epub 2012 Jun 7.

42.

Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis.

Sen N, Che X, Rajamani J, Zerboni L, Sung P, Ptacek J, Arvin AM.

Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):600-5. doi: 10.1073/pnas.1114232109. Epub 2011 Dec 21.

43.

Investigation of varicella-zoster virus neurotropism and neurovirulence using SCID mouse-human DRG xenografts.

Zerboni L, Arvin A.

J Neurovirol. 2011 Dec;17(6):570-7. doi: 10.1007/s13365-011-0066-x. Epub 2011 Dec 8. Review.

PMID:
22161683
44.

Structure-function analysis of varicella-zoster virus glycoprotein H identifies domain-specific roles for fusion and skin tropism.

Vleck SE, Oliver SL, Brady JJ, Blau HM, Rajamani J, Sommer MH, Arvin AM.

Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18412-7. doi: 10.1073/pnas.1111333108. Epub 2011 Oct 24.

45.

Apparent expression of varicella-zoster virus proteins in latency resulting from reactivity of murine and rabbit antibodies with human blood group a determinants in sensory neurons.

Zerboni L, Sobel RA, Lai M, Triglia R, Steain M, Abendroth A, Arvin A.

J Virol. 2012 Jan;86(1):578-83. doi: 10.1128/JVI.05950-11. Epub 2011 Oct 19.

46.

Varicella zoster virus ORF25 gene product: an essential hub protein linking encapsidation proteins and the nuclear egress complex.

Vizoso Pinto MG, Pothineni VR, Haase R, Woidy M, Lotz-Havla AS, Gersting SW, Muntau AC, Haas J, Sommer M, Arvin AM, Baiker A.

J Proteome Res. 2011 Dec 2;10(12):5374-82. doi: 10.1021/pr200628s. Epub 2011 Oct 26.

47.

A sequence within the varicella-zoster virus (VZV) OriS is a negative regulator of DNA replication and is bound by a protein complex containing the VZV ORF29 protein.

Khalil MI, Arvin A, Jones J, Ruyechan WT.

J Virol. 2011 Dec;85(23):12188-200. doi: 10.1128/JVI.05501-11. Epub 2011 Sep 21.

48.

Disruption of PML nuclear bodies is mediated by ORF61 SUMO-interacting motifs and required for varicella-zoster virus pathogenesis in skin.

Wang L, Oliver SL, Sommer M, Rajamani J, Reichelt M, Arvin AM.

PLoS Pathog. 2011 Aug;7(8):e1002157. doi: 10.1371/journal.ppat.1002157. Epub 2011 Aug 25.

49.

Varicella-zoster virus infection triggers formation of an interleukin-1β (IL-1β)-processing inflammasome complex.

Nour AM, Reichelt M, Ku CC, Ho MY, Heineman TC, Arvin AM.

J Biol Chem. 2011 May 20;286(20):17921-33. doi: 10.1074/jbc.M110.210575. Epub 2011 Mar 8.

50.

VZV: immunobiology and host response.

Arvin A, Abendroth A.

In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007. Chapter 39.

Supplemental Content

Support Center